Coronavirus COVID-19 Outbreak – What's New

William M. Detmer, MD, supported by the Unbound Medicine Team

Updated: Wednesday, January 13, 2021 17:24 ET

COVID-19 Cases

Around the Globe

New Cases in Countries with Highest COVID-19 Activity
New Cases in Countries with Highest COVID-19 Activity

Recent Confirmed Cases in countries with the highest reported COVID-19 activity (India, United States, Brazil, France, Russia, UK, Turkey, Italy, Spain). Note that the left axis is linear rather than logarithmic and representsthe number of cases reported (rolling 7-day average) by each country.

Click for Live Updates.

Data sources: Johns Hopkins Center for Systems Science and Engineering (CSSE). Our World in Data.

COVID-19 Outbreak Map by Johns Hopkins CSSE – Updated Hourly
Coronavirus 2019 COVID-19 Outbreak Map

Click one of the links below to see the latest.
Desktop | Mobile
Source: Johns Hopkins Center for Systems Science and Engineering (CSSE).[1]

In the United States

U.S. Key COVID-19 Metrics: January 13, 2021
U.S. Key COVID-19 Metrics - What's New

Key COVID-19 metrics in the United States since April 1, 2020. Dark lines represent 7-day averages.

Click for Live Updates.

Source: The COVID-19 Tracking Project[2]

US COVID-19 Case in last 7 Days: January 12, 2021
US COVID-19 Case in last 7 Days

US COVID-19 Case Rate Reported to the CDC in the Last 7 Days, by State/Territory (cases per 100K).

Click for Live Updates.

Source: US Centers for Disease Control and Prevention.

U.S. Deaths by State and County: Percent Change in Last 7 days
Coronavirus deaths in US by State and County

Aggregate data from the Centers for Disease Control and Prevention (CDC) and state- and local-level public health agencies. County-level data is confirmed by referencing state and local agencies directly. Map shows percent change in deaths from previous7 days as of January 3, 2020.

Click for Live Updates.

Source: US Centers for Disease Control

U.S. States with the Most COVID-19 Activity

Cases

Deaths

State

Total

Last 7d

Per 100k

Total

Last 7d

Per 100k

California

2,747,288

294,954

6,953

30,513

3,510

113

Texas

1,995,292

152,139

6,881

30,219

2,000

136

Florida

1,476,484

108,706

6,874

23,227

1,039

0

New York

665,919

73,401

6,024

14,050

887

144

Arizona

636,100

68,626

8,739

10,482

1,165

77

Georgia

773,692

67,538

7,287

11,662

590

91

North Carolina

635,975

60,579

6,064

7,638

642

180

Pennsylvania

733,429

59,514

5,729

18,080

1,534

116

Ohio

792,938

57,935

6,784

9,802

555

101

New Jersey

594,749

52,879

6,696

20,039

657

108

Illinois

1,040,168

48,449

8,208

19,497

935

0

New York City

506,377

43,709

6,029

25,742

379

109

Tennessee

660,874

43,225

9,677

8,011

744

74

Massachusetts

432,370

42,841

6,273

13,204

532

21

Indiana

570,477

37,394

8,474

9,104

441

133

Virginia

412,545

35,245

4,833

5,552

326

87

South Carolina

359,357

31,284

6,980

5,860

362

153

Oklahoma

346,621

29,076

8,760

2,858

216

135

Alabama

407,848

28,255

8,318

5,573

687

111

Kentucky

308,729

27,893

6,910

2,944

172

65

Louisiana

352,939

26,291

7,592

7,971

336

171

Michigan

570,150

23,508

5,709

14,296

688

191

Wisconsin

555,249

23,359

9,536

5,633

267

105

Maryland

314,867

21,963

5,208

6,404

272

33

Missouri

427,117

21,528

6,959

6,155

330

143

Utah

309,629

20,678

9,658

1,422

110

102

Arkansas

259,553

20,665

8,601

4,121

285

100

Connecticut

217,047

20,079

6,088

6,449

257

3

U.S. Centers for Disease Control.

What’s New Elsewhere

Feedback

Your feedback is appreciated!

Share this page

Share by emailShare by FacebookShare by Twitter

References

  1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020.  [PMID:32087114]
  2. Nationwide COVID-19 Metrics Since April 1. The COVID Tracking Project. [https://covidtracking.com/data/charts/us-all-key-metrics]
  3. Abbasi J. The Promise and Peril of Antibody Testing for COVID-19. JAMA. 2020.  [PMID:32301958]
  4. Angulo FJ, Finelli L, Swerdlow DL. Reopening Society and the Need for Real-Time Assessment of COVID-19 at the Community Level. JAMA. 2020.  [PMID:32412582]
  5. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996.  [PMID:32471884]
  6. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020.  [PMID:32445440]
  7. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020.  [PMID:32412710]
  8. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020.  [PMID:32492293]
  9. Brooks JT, Butler JC, Redfield RR. Universal Masking to Prevent SARS-CoV-2 Transmission-The Time Is Now. JAMA. 2020.  [PMID:32663243]
  10. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed 27 June 2020.
  11. Carfì A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020.  [PMID:32644129]
  12. Cavalcanti AB et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. July 23, 2020 DOI: 10.1056/NEJMoa2019014
  13. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020.  [PMID:32434946]
  14. Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020.  [PMID:32219057]
  15. Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020.  [PMID:32497510]
  16. Coronavirus Disease 2019 (COVID-19) Situation Reports. World Health Organization. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-...]
  17. Coronavirus Locations: COVID-19 Map by County and State. USAFacts.org. [https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/]
  18. Coronavirus in the U.S.: Latest Map and Case Count. New York Times. [https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html]
  19. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020.  [PMID:32598830]
  20. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020.  [PMID:32558485]
  21. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020.  [PMID:32598831]
  22. Gao Q, Bao L, Mao H, et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020.  [PMID:32376603]
  23. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020.  [PMID:32379955]
  24. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020.  [PMID:32459919]
  25. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020.  [PMID:32275812]
  26. Halfmann PJ, Hatta M, Chiba S, et al. Transmission of SARS-CoV-2 in Domestic Cats. N Engl J Med. 2020.  [PMID:32402157]
  27. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020.  [PMID:32692365]
  28. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020.  [PMID:32401715]
  29. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020.  [PMID:32663912]
  30. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions. JAMA. 2020.  [PMID:32391855]
  31. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367(6485):1412-1413.  [PMID:32217705]
  32. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020.  [PMID:32492084]
  33. Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020.  [PMID:32227757]
  34. Mahase E. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ. 2020;369:m2422.  [PMID:32546467]
  35. Mahase E. Covid-19: What is the evidence for cloth masks? BMJ. 2020;369:m1422.  [PMID:32265341]
  36. Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020.  [PMID:32450107]
  37. Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020.  [PMID:32303591]
  38. Morawska L, Milton DK. It is Time to Address Airborne Transmission of COVID-19. Clin Infect Dis. 2020.  [PMID:32628269]
  39. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 [News]. US National Institute of Allergy and Infectious Diseases. April 29, 2020. [https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-...]
  40. NIH clinical trial of investigational vaccine for COVID-19 begins: study enrolling Seattle-based healthy adult volunteers [News]. March 16, 2020. [https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investiga...]
  41. Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. Lancet. 2020;395(10236):1525-1527.  [PMID:32423580]
  42. Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020;395(10230):1101-1102.  [PMID:32247384]
  43. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020.  [PMID:32645347]
  44. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020.  [PMID:32678530]
  45. Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. U.S. Centers for Disease Control and Prevention. [https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-...]
  46. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020.  [PMID:32392282]
  47. Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 Vaccination Program. JAMA. 2020.  [PMID:32421155]
  48. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020.  [PMID:32374370]
  49. Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020.  [PMID:32269068]
  50. Situation update worldwide. European Centre for Disease Prevention and Control. [https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases]
  51. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. Ann Intern Med. 2020.  [PMID:32673060]
  52. Stringhini S et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. June 11, 2020. S0140-6736(20)31304-0. [https://doi.org/10.1016/]
  53. Studdert DM, Hall MA. Disease Control, Civil Liberties, and Mass Testing - Calibrating Restrictions during the Covid-19 Pandemic. N Engl J Med. 2020.  [PMID:32272003]
  54. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.  [PMID:32409561]
  55. Torjesen I. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ. 2020;369:m2263.  [PMID:32513810]
  56. Treon SP, Castillo J, Skarbnik AP, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood. 2020.  [PMID:32302379]
  57. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020.  [PMID:32410760]
  58. Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020.  [PMID:32532802]
  59. Wang X, Ferro EG, Zhou G, et al. Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA. 2020.  [PMID:32663246]
  60. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578.  [PMID:32423584]
  61. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020.  [PMID:32648899]
  62. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med. 2020.  [PMID:32502334]

Coronavirus COVID-19 Outbreak – What's Newis the Relief Central Word of the day!

Last updated: January 13, 2021